Study of BMS-986158 in Subjects With Select Advanced Cancers

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Inclusion Criteria:

• Must have select advanced cancers with specific genetic profiles
• Must have received appropriate standard of care
• At least one measurable lesion at baseline
• Expected to have life expectancy of at least 3 months
• Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria:

• Concomitant second malignancies
• Uncontrolled or significant cardiovascular disease
• Inadequate bone marrow function
• Chronic gastrointestinal illness
• Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor

Other protocol defined inclusion/exclusion criteria could apply